Antimicrobial peptide therapeutics for cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 2921-2927

  Zhang, Lijuan ^a,d   Parente, Jody ^a   Harris, Scott M ^a   Woods, Donald E ^b   Hancock, Robert E W ^c   Falla, Timothy J ^a  

^a Helix Biomedix Inc   (United States)

^b Health Sciences Centre Calgary   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETAMETHASONE; CHLORAMPHENICOL; CITRATE SODIUM; DIVALENT CATION; IMIPENEM; LYSYLTRYPTOPHYLLYSYLLYSYLPHENYLALANYLISOLEUCYLLYSYLLYSYLISOLEUCYLGLYCYLISOL EUCYLGLYCYLGALANYLVALYLLEUCYLLYSYLVALYLLEUCYLTHREONYLTHREONYLGLYCYLLEUCYLPROLYLA LANYLLEUCYLLYSYLLEUCYLTHREONYLLYSYLLYSINAMIDE; LYSYLTRYPTOPHYLLYSYLLYSYLPHENYLALANYLISOLEUCYLLYSYLSERYLLEUCYLTHREONYLLYSYL SERYLALANYLALANYLLYSYLTHREONYLVALYLVALYLLYSYLTHREONYLALANYLLYSYLLYSYLPROLYLLEUCY LISOLEUCYLVALINAMIDE; LYSYLTRYPTOPHYLLYSYLSERYLPHENYLALANYLISOLEUCYLLYSYLLYSYLLEUCYLTHREONYLLYSYL ALANYLALANYLLYSYLLYSYLVALYLVALYLTHREONYLTHREONYLALANYLLYSYLLYSYLPROLYLLEUCYLISOL EUCYLVALINAMIDE; METICILLIN; MUCIN; PEPTIDE; PHENYLALANYLALANYLLYSYLLYSLLEUCYLALANYLLYSLLYSYLLEUCYLLYSYLLYSYLLEUCYLALANY LLYSYLLYSYLALANYLLYSINE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; SODIUM CHLORIDE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ACHROMOBACTER XYLOSOXIDANS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE COURSE; HUMAN; INFLAMMATION; INOCULATION; LUNG INFECTION; LUNG INJURY; MALE; MOUSE; MULTIDRUG RESISTANCE; NEBULIZER; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; EAR DISEASES; EDEMA; GRAM-NEGATIVE BACTERIA; HUMANS; LUNG DISEASES; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PSEUDOMONAS AERUGINOSA; RATS; STAPHYLOCOCCUS AUREUS;

EID: 21444442023     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.2921-2927.2005     Document Type: Article

References (35)

1. Alonso, A., F. Rojo, and J. L. Martinez. 1999. Environmental and clinical isolates of Pseudomonas aeruginosa show pathogenic and biodegradative properties irrespective of their origin. Environ. Microbiol. 1:421-430.
2. Baconnais, S., R. Tirouvanziam, J. M. Zahm, S. de Bentzmann, B. Peault, G. Balossier, and E. Puchelle. 1999. Ion composition and rheology of airway liquid from cystic fibrosis fetal tracheal xenografts. Am. J. Respir. Cell Mol. Biol. 20:605-611.
3. Bals, R., X. Wang, Z. Wu, T. Freeman, V. Bafna, M. Zasloff, and J. M. Wilson. 1998. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Investig. 102:874-880.
4. Bals, R., D. J. Weiner, R. L. Meegalla, and J. M. Wilson. 1999. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J. Clin. Investig. 103:1113-1117.
5. Beaulac, C., S. Sachetelli, and J. Lagace. 1999. Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa. J. Drug Targeting 7:33-41.
6. Bowdish, D. M. E., D. J. Davidson, and R. E. W. Hancock. 2004. The role of host defence and related peptides in immunity. Curr. Prot. Peptide Sci. 6:35-51.
7. Cash, H. A., D. E. Woods, B. McCullough, W. G. Johanson, Jr., and J. A. Bass. 1979. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 119:453-459.
8. Chang, J., E. Blazek, M. Skowronek, L. Marinari, and R. P. Carlson. 1987. The antiinflammatory action of guanabenz is mediated through 5-lipoxygenase and cyclooxygenase inhibition. Eur. J. Pharmacol. 142:197-205.
9. Clermont, D., C. Harmant, and C. Bizet. 2001. Identification of strains of Alcaligenes and Agrobacterium by a polyphasic approach. J. Clin. Microbiol. 39:3104-3109.
10. Duranton, J., D. Belorgey, J. Carrere, L. Donato, T. Moritz, and J. G. Bieth. 2000. Effect of DNase on the activity of neutrophil elastase, cathepsin G and proteinase 3 in the presence of DNA. FEBS Lett. 473:154-156.
11. Finlay, B. B., and R. E. W. Hancock. 2004. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2:497-504.
12. Ford, A. S., A. L. Baltch, R. P. Smith, and W. Ritz. 1993. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. J. Antimicrob. Chemother. 31:523-532.
13. Gallo, R. L., M. Murakami, T. Ohtake, and M. Zaiou. 2002. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 110:823-831.
14. Gaylor, A. S., and J. C. Reilly. 2002. Therapy with macrolides in patients with cystic fibrosis. Pharmacotherapy 22:227-239.
15. Goldman, M. J., G. M. Anderson, E. D. Stolzenberg, U. P. Kari, M. Zasloff, and J. M. Wilson. 1997. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88:553-560.
16. Grimwood, K., M. To, H. R. Rabin, and D. E. Woods. 1989. Subinhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model. J. Antimicrob. Chemother. 24:937-945.
17. Halmerbauer, G., S. Arri, M. Schierl, E. Strauch, and D. Y. Koller. 2000. The relationship of eosinophil granule proteins to ions in the sputum of patients with cystic fibrosis. Clin. Exp. Allergy 30:1771-1776.
18. Hancock, R. E. W., and A. Patrzykat. 2002. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr. Drug. Targets Infect. Disord. 2:79-83.
19. Hodson, M. E. 1995. Maintenance treatment with antibiotics in cystic fibrosis patients. Sense or nonsense? Neth. J. Med. 46:288-292.
20. Jensen, T., S. S. Pedersen, S. Garne, C. Heilmann, N. Hoiby, and C. Koch. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19:831-838.
21. Koczulla, A. R., and R. Bals. 2003. Antimicrobial peptides: current status and therapeutic potential. Drugs 63:389-406.
22. Lester, A., and J. J. Andreasen. 1988. In vitro susceptibility of Pseudomonas aeruginosa from bacteremic and fibrocystic patients to four quinolones and five other antipseudomonal antibiotics. Scand. J. Infect. Dis. 20:525-529.
23. Minkwitz, A., and G. Berg. 2001. Comparison of antifungal activities and 16S ribosomal DNA sequences of clinical and environmental isolates of Stenotrophomonas maltophilia. J. Clin. Microbiol. 39:139-145.
24. Omri, A., Z. E. Suntres, and P. N. Shek. 2002. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 64:1407-1413.
25. Rajan, S., and L. Saiman. 2002. Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17:47-56.
26. Saiman, L., and J. Siegel. 2003. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am. J. Infect. Control. 31:S1-S62.
27. Sajjan, U. S., L. T. Tran, N. Sole, C. Rovaldi, A. Akiyama, P. M. Friden, J. F. Forstner, and D. M. Rothstein. 2001. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob. Agents Chemother. 45:3437-3444.
28. Scott, M. G., H. Yan, and R. E. W. Hancock. 1999. Biological properties of structurally related alpha-helical cationic antimicrobial peptides. Infect. Immun. 67:2005-2009.
29. Steinberg, D. A., M. A. Hurst, C. A. Fujii, A. H. Kung, J. F. Ho, F. C. Cheng, D. J. Loury, and J. C. Fiddes. 1997. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob. Agents Chemother. 41:1738-1742.
30. Trezise, A. E., C. Szpirer, and M. Buchwald. 1992. Localization of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) in the rat to chromosome 4 and implications for the evolution of mammalian chromosomes. Genomics 14:869-874.
31. Unertl, K., G. Ruckdeschel, H. K. Selbmann, U. Jensen, H. Forst, F. P. Lenhart, and K. Peter. 1987. Prevention of colonization and respiratory infections in long-term ventilated patients by local antimicrobial prophylaxis. Intensive Care Med. 13:106-113.
32. Woods, D. E., P. A. Sokol, L. E. Bryan, D. G. Storey, S. J. Mattingly, H. J. Vogel, and H. Ceri. 1991. In vivo regulation of virulence in Pseudomonas aeruginosa associated with genetic rearrangement. J. Infect. Dis. 163:143-149.
33. Zabner, J., J. J. Smith, P. H. Karp, J. H. Widdicombe, and M. J. Welsh. 1998. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol. Cell. 2:397-403.
34. Zhang, L., M. G. Scott, H. Yan, L. D. Mayer, and R. E. W. Hancock. 2000. Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry 39:14504-14514.
35. Zhang, Y., and J. F. Engelhardt. 1999. Airway surface fluid volume and Cl content in cystic fibrosis and normal bronchial xenografts. Am. J. Physiol. 276:C469-C476.